Revance Therapeutics
Newark
About Revance Therapeutics
Revance Therapeutics is a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $1.7B
- Funding stage: M&A
- Last round: Post-IPO Equity (Mar 2024)
- Ticker: nasdaq:RVNC
- Website: revance.com
- Phone: +1 510 742 3400
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/revance-therapeutics-84384 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.